<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1953">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04577534</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2020-002039-31</org_study_id>
    <secondary_id>2020-002039-31</secondary_id>
    <secondary_id>T124/2020</secondary_id>
    <secondary_id>KLnro 36/2020</secondary_id>
    <secondary_id>dnro 68/06.00.01/2020</secondary_id>
    <nct_id>NCT04577534</nct_id>
  </id_info>
  <brief_title>COVID-19: Salvage TOcilizumab as a Rescue Measure</brief_title>
  <acronym>COVIDSTORM</acronym>
  <official_title>COVID-19: Salvage TOcilizumab as a Rescue Measure. Use of Tocilizumab in the Inflammatory Phase of COVID-19 / New Coronavirus Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jarmo Oksi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluating the efficacy of Tocilizumab in hospitalized patients in the inflammatory phase of&#xD;
      COVID-19. Randomization 2:1 (TCZ:standard of care).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical status at day 28</measure>
    <time_frame>day 28</time_frame>
    <description>(assessed using 7-category ordinal scale) 7 death 6 in ICU with ECMO/ mechanical ventilation 5 in ICU, no ECMO/ mechanical ventilation 4 in hospital, not ICU, needs supplementary oxygen 3 in hospital, not ICU, no supplementary oxygen 2 not in hospital, but not back to normal&#xD;
1 not in hospital, back to normal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to clinical improvement</measure>
    <time_frame>28 days</time_frame>
    <description>defined as a National Early Warning Score 2 (NEWS2) of&gt;/=2 maintained for 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to decline of at least 2 categories</measure>
    <time_frame>28 days</time_frame>
    <description>relative on a 7-category ordinalscale of clinical status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of mechanical and/or non-invasive ventilation</measure>
    <time_frame>28 days</time_frame>
    <description>(mode and duration of respiratory support) Hospital day when respiratory support needed with non-invasive ventilation - and duration.&#xD;
Hospital day when respiratory support needed by invasive mechanical ventilation -and duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventilator-free days to day 28</measure>
    <time_frame>28 days</time_frame>
    <description>days not in ventilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ failure free days to day 28</measure>
    <time_frame>28 days</time_frame>
    <description>days without organ failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ICU stay</measure>
    <time_frame>28 days</time_frame>
    <description>ICU admission day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU stay</measure>
    <time_frame>28 days</time_frame>
    <description>days on ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical failure</measure>
    <time_frame>28 days</time_frame>
    <description>time to death, mechanical ventilation, or ICU admission (whichever occurs first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAPS II</measure>
    <time_frame>28 days</time_frame>
    <description>during ICU stay SAPS II = simplified acute physiology score II min 0 (best), max 163 (worst)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCI</measure>
    <time_frame>28 days</time_frame>
    <description>during ICU stay CCI = Charlson Comorbidity Index min 0 (best), max 37 (worst)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APACHE II</measure>
    <time_frame>28 days</time_frame>
    <description>during ICU stay APACHE II = acute physiology and chronic health evaluation II min 0 (best), max 71 (worst)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA 6</measure>
    <time_frame>28 days</time_frame>
    <description>during ICU stay SOFA 6 = sequential organ failure assessment min 0 (best), max 24 (worst)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>28 days</time_frame>
    <description>during and end of period of 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hospital discharge or &quot;ready for discharge&quot;</measure>
    <time_frame>28 days</time_frame>
    <description>as evidenced by normal body temperature and respiratory rate and stable oxygen saturation on ambient air or &lt;/=2 l supplemental oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of supplemental oxygen</measure>
    <time_frame>28 days</time_frame>
    <description>days on suppl oxygen</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Tocilizumab (TCZ)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive one infusion of iv TCZ (according to weight of patient)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard of care (no TCZ)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will receive standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iv Tocillizumab (TCZ)</intervention_name>
    <description>Participants are randomized (2:1) to receive TCZ or Standard of Care</description>
    <arm_group_label>Tocilizumab (TCZ)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  written informed consaent obtained&#xD;
&#xD;
          -  hospitalized with COVID-19 disease&#xD;
&#xD;
          -  Age &gt;/= 18 years&#xD;
&#xD;
          -  SARS CoV-2 NhO posit&#xD;
&#xD;
          -  Sp=2 &lt;/93% on ambient air or respiratory rate &gt;30 /min&#xD;
&#xD;
          -  Any 2 of the 4: P-IL-6 &gt; 2 x ULN / P-ferritin &gt; 2 x ULN / P-FIDD &gt;1.5 mg/l / P- CRP&#xD;
             &gt;40 mg/l without obvious presence of bacterial infection (normal values: P -IL-6 &lt;5.9&#xD;
             ng/l; P-ferritin, men 30-400 mikrog/l, women 13-150 mikrog/l ; P-FIDD (Fibrin&#xD;
             degradation products, D-dimer) &lt;0.5 mg/l; P-CRP &lt;10 mg/l)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known severe allergic reactions to monoclonal antibodies&#xD;
&#xD;
          -  Active confirmed tuberculosis with ongoing treatment or obvious tuberculosis or&#xD;
             obvious other bacterial, fungal or viral infection (besides COVID-19)&#xD;
&#xD;
          -  In the opinion of the clinical team, progression to death is imminent and inevitable&#xD;
             within the next 24 hours, irrespective of the provision of treatments&#xD;
&#xD;
          -  Long-term oral anti-rejection or immunomodulatory drugs (including corticosteroids&#xD;
             equivalent to methylprednison 15mg/day)&#xD;
&#xD;
          -  Pregnant or lactating women. If needed, exclusion of pregnancy should be performed by&#xD;
             laboratory test (U-hCG-O).&#xD;
&#xD;
          -  Participating in other drug clinical trials&#xD;
&#xD;
          -  Absolute neutrophil count &lt; 1 x10E9/l&#xD;
&#xD;
          -  Platelet count &lt;50 x10E9/l&#xD;
&#xD;
          -  ALAT &gt;10x ULN&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jarmo Oksi, prof</last_name>
    <phone>+358 40 5414813</phone>
    <email>jarmo.oksi@utu.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 3, 2020</study_first_submitted>
  <study_first_submitted_qc>October 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Jarmo Oksi</investigator_full_name>
    <investigator_title>Head of Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>new coronavirus disease</keyword>
  <keyword>tocilizumab</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>plan to investigate if it is possible by law</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

